Advanced Bifurcation Systems Stent to Simplify an Increasingly Common Procedure

Now at pre-submission stage with FDA, company’s patented mother-daughter stent product includes two independently movable catheters that enable automatic alignment and accurate positioning

LIVERMORE, Calif. – September 25, 2019 /MarketersMedia/ —

Studies show that angioplasty operations succeed in opening clogged arteries about 90 percent of the time. On average, though, 30 to 40 percent of patients will experience subsequent narrowing unless a stent is present to prevent it.

Inserting a simple, linear stent into the coronary artery tends to be fairly straightforward. A 2014 study published in Heart Asia, however, described difficulties faced by doctors tasked with carrying out the 15 to 20 percent of all percutaneous coronary interventions that center on a coronary bifurcation. In many cases, those challenges see physicians opting to implant a single stent even though the lesion in question affects both the artery and the adjacent daughter vessel.

With its revolutionary platform now working its way through the regulatory approval process, Advanced Bifurcation Systems (ABS) aims to lead a “paradigm shift in interventional cardiology that benefits all parties.” The ABS solution will enable improved healthcare for patients, as doctors will become able to implant true bifurcated stents using the same techniques they employ for linear ones.

As the resources at https://www.advancedbifurcation.com/the-abs-product-platform/ detail, this is made possible through the use of proprietary technologies which have earned Advanced Bifurcation Systems 36 patents, with another 12 pending. The ABS platform includes two independently positionable stent catheters and markers that enable automatic alignment and precise positioning.

In addition to the obvious benefits for patients with bifurcation disease and their doctors, the ABS platform will also be advantageous for hospitals and insurers. Shortened procedure times will help hospitals improve catheter lab utilization while boosting bifurcation treatment revenues. Insurance companies will benefit from reduced costs, thanks to a marked reduction in materials and procedure times.

Last year, Family Office Networks announced a partnership with ABS arranged because of the potential inherent in the company’s technology. ABS also chose a production facility in Livermore last August that will be certified to manufacture its bifurcation stent as the company moves closer to a planned FDA application for review.

With the global coronary stent market expected to hit $25 billion by 2025, and bifurcation legions accounting for up to one-fifth of all cases, the need for the ABS product platform could hardly be clearer. Videos available at https://www.advancedbifurcation.com/the-abs-product-platform/clinical-case-demonstrations/ reveal how the company’s bifurcation stent works in practice under actual clinical conditions.

About Advanced Bifurcation Systems:

Advancing the boundaries of medical science with its revolutionary mother-daughter stent platform, Advanced Bifurcation Systems is committed to overseeing a much-needed paradigm shift in interventional cardiology.

Contact Info:
Name: Ashur Bourang
Email: Send Email
Organization: Advanced Bifurcation Systems
Address: Livermore, CA, 94551
Phone: 877-895-0848
Website: https://www.advancedbifurcation.com

Source URL: https://marketersmedia.com/advanced-bifurcation-systems-stent-to-simplify-an-increasingly-common-procedure/88922402

Source: MarketersMedia

Release ID: 88922402